The global generic injectables market is projected to expand from USD 149.82 billion in 2026 to USD 285.61 billion by 2031, after being valued at USD 131.68 billion in 2025, according to a ResearchAndMarkets report that forecasts a 13.77% compound annual growth rate over 2026-2031. The study says growth is being driven by the loss of patent protection for branded injectable drugs, rising demand for lower-cost oncology and anti-infective treatments, broader biosimilar (near-copy biologic medicine) approvals, and hospitals' growing preference for ready-to-use formats. Oncology generated 33.26% of market revenue in 2025 and is expected to post a 16.55% CAGR through 2031, while prefilled syringes are forecast to grow 16.38% as providers seek simpler preparation and safer handling. The report also highlights supply-side constraints, especially sterile fill-finish (aseptic final drug production and packaging) capacity, which can slow commercialization despite regulatory approvals. Regionally, North America accounted for 36.78% of global revenue in 2024, while Asia-Pacific is expected to grow fastest at a 16.43% CAGR, supported in part by India's roughly USD 2 billion Production Linked Incentive program and China's closer alignment with International Council for Harmonisation guidelines.